Loading...

Philip Mack

TitleADJ PROF-HCOMP
InstitutionUniversity of California Davis
DepartmentMED INT MED - HEMATOLOGY/ONCOL
AddressCancer Ctr So #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy G, Ignatius Ou SH, Stephens PJ, McPherson J, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack P, Schrock AB. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Jul 05. PMID: 29981927.
      View in: PubMed
    2. Rolfo C, Mack P, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DS, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2018 Jun 06. PMID: 29885479.
      View in: PubMed
    3. Zill OA, Banks KC, Fairclough SR, Mortimer S, Vowles JV, Mokhtari R, Gandara DR, Mack P, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res. 2018 May 18. PMID: 29776953.
      View in: PubMed
    4. Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack P, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888. PMID: 29801011.
      View in: PubMed
    5. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 May; 81(5):957-963. PMID: 29520435.
      View in: PubMed
    6. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack P, Cross DAE. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 May; 17(5):885-896. PMID: 29483211.
      View in: PubMed
    7. Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst. 2018 Jan 13. PMID: 29346580.
      View in: PubMed
    8. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack P, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 Jan; 19(1):101-114. PMID: 29169877.
      View in: PubMed
    9. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack P, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    10. West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2018 Jan; 19(1):84-92. PMID: 28801183.
      View in: PubMed
    11. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack P, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 Dec; 15(6):635-641. PMID: 28579151.
      View in: PubMed
    12. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack P. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. PMID: 28736761.
      View in: PubMed
    13. Gandara DR, Riess JW, Kelly K, Li T, Mack P, Lara PN. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. PMID: 28082049.
      View in: PubMed
    14. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack P. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):281-285. PMID: 28038979.
      View in: PubMed
    15. Mack P, Banks KC, Zill OA, Mortimer SA, Chudova DI, Odegaard J, Lee CE, Nagy RJ, Eltoukhy H, Talasaz A, Lanman R, Gandara DR. O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations. J Thorac Oncol. 2016 Oct; 11(10S):S168-S169. PMID: 27676472.
      View in: PubMed
    16. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack P, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63. PMID: 27229180.
      View in: PubMed
    17. Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack P, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. PMID: 26725184; PMCID: PMC4775366 [Available on 03/01/17].
    18. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack P, Gandara DR. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. PMID: 26498504.
      View in: PubMed
    19. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack P, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. PMID: 26301689; PMCID: PMC4734742.
    20. Gandara DR, Lara PN, Mack P. Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015 Sep 10; 33(26):2839-40. PMID: 26215942.
      View in: PubMed
    21. Lara PN, Longmate J, Mack P, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. PMID: 26106072; PMCID: PMC4592395 [Available on 10/01/16].
    22. Mack P. Plasma-based tumor genetics for monitoring disease progression: what can we learn from a tube of blood? J Thorac Oncol. 2015 Apr; 10(4):546-7. PMID: 25789830; PMCID: PMC4573951.
    23. Gandara DR, Mack P, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. PMID: 25838158; PMCID: PMC4586173.
    24. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack P, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24. PMID: 25680375; PMCID: PMC4654466.
    25. Ou SH, Moon J, Garland LL, Mack P, Testa JR, Tsao AS, Wozniak AJ, Gandara DR. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91. PMID: 25611229; PMCID: PMC4304604.
    26. Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack P, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7. PMID: 25703100; PMCID: PMC4497941.
    27. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack P, Gandara DR. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. PMID: 25490004; PMCID: PMC4320001.
    28. Holland WS, Chinn DC, Lara PN, Gandara DR, Mack P. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015 Apr; 141(4):615-26. PMID: 25323938; PMCID: PMC4562434.
    29. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack P, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. PMID: 25219358; PMCID: PMC4323674.
    30. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. PMID: 25091263; PMCID: PMC4318776.
    31. Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack P, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10; 32(23):2463-70. PMID: 25002722; PMCID: PMC4121504.
    32. Chinn DC, Holland WS, Mack P. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. J Cancer Res Clin Oncol. 2014 Jul; 140(7):1137-49. PMID: 24756365; PMCID: PMC4565522.
    33. Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack P, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 2014 Aug 01; 120(15):2343-51. PMID: 24752945; PMCID: PMC4140446.
    34. Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN, Mack P, David EA. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40. PMID: 24746995.
      View in: PubMed
    35. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack P, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. PMID: 24616308; PMCID: PMC3970171.
    36. Lara PN, Ely B, Quinn DI, Mack P, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. PMID: 24565955; PMCID: PMC3982883.
    37. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack P, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. PMID: 24189513; PMCID: PMC4072123.
    38. Twardowski PW, Mack P, Lara PN. Papillary renal cell carcinoma: current progress and future directions. Clin Genitourin Cancer. 2014 Apr; 12(2):74-9. PMID: 24629521.
      View in: PubMed
    39. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack P. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. PMID: 24176733; PMCID: PMC4586161.
    40. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack P, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. PMID: 24013936; PMCID: PMC4562389.
    41. Kelly K, Chansky K, Mack P, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. PMID: 23910067; PMCID: PMC4122504.
    42. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack P, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. PMID: 23871417; PMCID: PMC4277263.
    43. Maus MK, Mack P, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. PMID: 23470290.
      View in: PubMed
    44. Li T, Kung HJ, Mack P, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10; 31(8):1039-49. PMID: 23401433; PMCID: PMC3589700.
    45. Mack P, Gandara DR, Lara PN. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1591-6. PMID: 23253224.
      View in: PubMed
    46. Gandara DR, Li T, Lara PN, Mack P, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. PMID: 22677432; PMCID: PMC4049356.
    47. Mahaffey CM, Mahaffey NC, Holland W, Zhang H, Gandara DR, Mack P, Forman HJ. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol. 2012 Jan; 7(1):34-9. PMID: 22089114; PMCID: PMC3241903.
    48. Wilson PM, LaBonte MJ, Lenz HJ, Mack P, Ladner RD. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. Mol Cancer Ther. 2012 Mar; 11(3):616-28. PMID: 22172489.
      View in: PubMed
    49. Sangha R, Davies AM, Lara PN, Mack P, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. PMID: 21892109; PMCID: PMC3219834.
    50. Semrad TJ, Mack P. Fibroblast growth factor signaling in non-small-cell lung cancer. Clin Lung Cancer. 2012 Mar; 13(2):90-5. PMID: 21959109.
      View in: PubMed
    51. Bai L, Yang JC, Ok JH, Mack P, Kung HJ, Evans CP. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2012 Jun 01; 130(11):2693-702. PMID: 21792888.
      View in: PubMed
    52. Chinn DC, Holland WS, Yoon JM, Zwerdling T, Mack P. Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer. 2012 Jun; 58(6):885-90. PMID: 21796766.
      View in: PubMed
    53. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack P, Lara PN. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012 Jan; 69(1):185-94. PMID: 21644050; PMCID: PMC4562405.
    54. Rothschild SI, Gautschi O, Lara PN, Mack P, Gandara DR. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol. 2011 Mar; 23(2):150-7. PMID: 21119513.
      View in: PubMed
    55. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack P, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. PMID: 21273177; PMCID: PMC3777729.
    56. Gandara DR, Grimminger P, Mack P, Lara PN, Li T, Danenberg PV, Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. PMID: 20975603.
      View in: PubMed
    57. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack P, Lara PN, Gandara DR. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. PMID: 20967484; PMCID: PMC3277821.
    58. Herbst RS, Kelly K, Chansky K, Mack P, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 01; 28(31):4747-54. PMID: 20921467; PMCID: PMC3020704.
    59. Ramalingam SS, Belani CP, Mack P, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84. PMID: 20559150; PMCID: PMC2911495.
    60. Dorff TB, Goldman B, Pinski JK, Mack P, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. PMID: 20484019; PMCID: PMC2898710.
    61. Gandara DR, Mack P, Li T, Lara PN, Herbst RS. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. PMID: 20681067.
      View in: PubMed
    62. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack P, Gandara DR, Davies AM. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. PMID: 20148348; PMCID: PMC4559347.
    63. Li T, Lara PN, Mack P, Perez-Soler R, Gandara DR. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. PMID: 19839922.
      View in: PubMed
    64. Mack P, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN, Davies AM, Gandara DR. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009 Dec; 4(12):1466-72. PMID: 19884861.
      View in: PubMed
    65. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack P, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01; 27(34):5788-93. PMID: 19884559; PMCID: PMC2793000.
    66. Gandara DR, Mack P, Li T, Lara PN, Herbst RS. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. PMID: 19900855.
      View in: PubMed
    67. Van Veldhuizen PJ, Hussey M, Lara PN, Mack P, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol. 2009 Oct; 32(5):453-9. PMID: 19487915; PMCID: PMC3394591.
    68. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K, Mack P. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol. 2009 Sep; 4(9):1104-10. PMID: 19620934.
      View in: PubMed
    69. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack P. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul 20; 27(21):3540-6. PMID: 19470925; PMCID: PMC2717760.
    70. Gandara DR, Lara PN, Mack P, Scagliotti G. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009 May; 10(3):148-50. PMID: 19443333.
      View in: PubMed
    71. McCall JL, Burich RA, Mack P. GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines. Leuk Res. 2010 Jan; 34(1):69-76. PMID: 19394691.
      View in: PubMed
    72. Mahaffey CM, Zhang H, Rinna A, Holland W, Mack P, Forman HJ. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radic Biol Med. 2009 Jun 15; 46(12):1650-7. PMID: 19345732; PMCID: PMC2692873.
    73. Purnell PR, Mack P, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. PMID: 19240653; PMCID: PMC2716757.
    74. Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009 Apr; 32(2):115-21. PMID: 19307945.
      View in: PubMed
    75. Sangha R, Lara PN, Mack P, Gandara DR. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol. 2009 Mar; 21(2):116-23. PMID: 19532012.
      View in: PubMed
    76. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack P, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. PMID: 19169683.
      View in: PubMed
    77. Mack P, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10; 26(29):4771-6. PMID: 18779603; PMCID: PMC2653139.
    78. Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack P, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008 Sep; 3(9):1026-31. PMID: 18758306; PMCID: PMC3523698.
    79. Burich RA, Holland WS, Vinall RL, Tepper C, White RW, Mack P. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int. 2008 Nov; 102(10):1458-66. PMID: 18565171.
      View in: PubMed
    80. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack P, Kung HJ. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. PMID: 18381431.
      View in: PubMed
    81. Gautschi O, Heighway J, Mack P, Purnell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15; 14(6):1639-48. PMID: 18347165.
      View in: PubMed
    82. Gautschi O, Mack P, Davies AM, Jablons DM, Rosell R, Gandara DR. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions. Clin Lung Cancer. 2008; 9 Suppl 3:S129-38. PMID: 19419927.
      View in: PubMed
    83. Sangha R, Lara PN, Mack P, Gandara DR. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. Clin Lung Cancer. 2008; 9 Suppl 3:S90-1. PMID: 19419929.
      View in: PubMed
    84. Mahaffey CM, Davies AM, Lara PN, Pryde B, Holland W, Mack P, Gumerlock PH, Gandara DR. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007 Nov; 8(9):548-53. PMID: 18186959.
      View in: PubMed
    85. Davies AM, Lara PN, Mack P, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4647-51. PMID: 17671158.
      View in: PubMed
    86. Ryan CW, Goldman BH, Lara PN, Mack P, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007 Aug 01; 25(22):3296-301. PMID: 17664477.
      View in: PubMed
    87. Ho C, Davies A, Mack P, Gandara D. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. Clin Lung Cancer. 2007 Jul; 8(7):420-4. PMID: 17681094.
      View in: PubMed
    88. Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack P, de Vere White RW. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007 Apr 01; 67(5):521-35. PMID: 17252539.
      View in: PubMed
    89. Gandara DR, Davies AM, Gautschi O, Mack P, Lau DH, Lara PN, Hirsch FR. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. PMID: 17382026.
      View in: PubMed
    90. Lara PN, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack P, Crowley JJ, Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006 Nov; 1(9):996-1001. PMID: 17409985.
      View in: PubMed
    91. Gautschi O, Mack P, Davies AM, Lara PN, Gandara DR. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer. 2006 Sep; 8(2):93-8. PMID: 17026809.
      View in: PubMed
    92. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 May; 7(6):385-8. PMID: 16800963.
      View in: PubMed
    93. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. PMID: 16384543.
      View in: PubMed
    94. Lara PN, Bold RJ, Mack P, Davies AM, Gumerlock PH, Gandara DR. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S67-71. PMID: 16250931.
      View in: PubMed
    95. Davies AM, Lara PN, Mack P, Gumerlock PH, Bold RJ, Gandara DR. Bortezomib-based combinations in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S59-63. PMID: 16250929.
      View in: PubMed
    96. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. PMID: 16000614.
      View in: PubMed
    97. Lara PN, Mack P, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15; 11(12):4444-50. PMID: 15958629.
      View in: PubMed
    98. Mack P, Jones AA, Gustafsson MH, Gandara DR, Gumerlock PH, Goldberg Z. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat Res. 2004 Dec; 162(6):623-34. PMID: 15548112.
      View in: PubMed
    99. Lara PN, Gumerlock PH, Mack P, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. PMID: 15476595.
      View in: PubMed
    100. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack P, Kung HJ, deVere White RW. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate. 2004 Aug 01; 60(3):257-71. PMID: 15176055.
      View in: PubMed
    101. Davies AM, Mack P, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. PMID: 19777702.
      View in: PubMed
    102. Lara PN, Davies AM, Mack P, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004 Feb; 31(1 Suppl 1):40-6. PMID: 14981579.
      View in: PubMed
    103. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack P, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. PMID: 14581348.
      View in: PubMed
    104. Lara PN, Frankel P, Mack P, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. PMID: 14555506.
      View in: PubMed
    105. Mack P, Davies AM, Lara PN, Gumerlock PH, Gandara DR. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S89-96. PMID: 12867067.
      View in: PubMed
    106. Davies AM, Lara PN, Mack P, Gandara DR. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr; 4(4):553-65. PMID: 12667118.
      View in: PubMed
    107. Mack P, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003 Apr; 51(4):337-48. PMID: 12721762.
      View in: PubMed
    108. Davies AM, Gandara DR, Lara PN, Mack P, Lau DH, Gumerlock PH. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. PMID: 14720340.
      View in: PubMed